Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (21189)	5/19/1998 10:20:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 32384

The dose limiting toxicity results on 1550 were extremely impressive. However, I was a bit concerned about the side effect profile of Panretin (oral, I think) recently released. I know the subjects were taking a variety of other drugs but wouldn't baseline have been measured including those drugs? In which case Panretin or Panretin interactions would be largely responsible for the side effects? I guess its hard to say much when the patients' immune systems are so heavily comprimised.